Prometheon Pharma is shaping the future of drug delivery with its patented Topicon™ formulation for the creation of transdermal patches and topical gel products for truly passive delivery of large and small molecule drugs across skin. We call them TruePatch™ because they don't use microneedles (often referred to as "protrusions"​ or "extensions") to puncture the skin surface. A TruePatch™ is applied just like other prescription patches. Prometheon is developing convenient 7-day, affordable, and truly needle-free TruePatch™ products, such as a basal insulin TruePatch™ to reverse prediabetes (5X larger new prevention market) and to treat established diabetes among increasing numbers of people, rich or poor, in every corner of the world. For the first time, we can talk about curing early type 2 diabetes and reversing the natural history of disease progression of prediabetes to established and irreversible type 2 diabetes. That's right. CURING and PREVENTING type 2 diabetes. Our insulin patch can become the first-line therapy for prediabetes/diabetes. No more injections. No more pills. No more inhaled drugs.At Prometheon, we foresee a future without daily injection of insulin, growth hormone, and other large molecule drugs. We imagine once-weekly drug cocktail patches for psychiatric disorders and chronic infectious diseases (e.g. TB, HIV) that maximize adherence to and benefit from prescribed therapies by simplifying drug administration. We see fields and streams absent of medical waste because our scientists exhaust every effort in creating biodegradable products and manufacturing processes that are mindful of the fragile ecosystems on our planet.New Editorial Board Appointments1) 2015-present, Editor, Pharmacy and Pharmacology International Journal2) 2015-present, Associate Editor, Diabetes Research Open Journal3) 2015-present, Member, International Journal of Vaccines and Vaccination4) 2016-present, Member, Open Access Journal of Science and Technology

Endowed Chair, DCI Dialysis & Nephrology Practice Group (Jacksonville)Division of Nephrology, Hypertension and Renal TransplantationDepartments of Medicine and Microbiology & Molecular GeneticsCollege of MedicineUniversity of FloridaHonors and Awards1) 2009 Clinical Translational Science Institute Scholar Award, University of Florida, Gainesville, FL2) 2010 Excellence in Teaching Award, Department of Medicine, University of Florida, Gainesville, FL3) 2010 Donald Etzweiler Visiting Scholar, International Diabetes Center, Minneapolis, MN4) 2011 Semi-Finalist (“Sweet Sixteen”), 2nd Annual Cade Museum Prize for Innovation Award (USA)5) 2012 Finalist (“Final Four”), 3rd Annual Cade Museum Prize for Innovation Award (USA)Hospital or Affiliated Institution Appointmnts1) 2008-2012 Physician, UF&Shands Hospital, Gainesville, FL2) 2008-2012 Physician, Malcolm Randall VA Hospital, Gainesville, FL3) 2008-2012 Physician, Select Specialty Hospital, Gainesville, FL4) 2011-2012 Member, Moffitt Cancer Research Center’s Cancer Center Support Grant Program, Tampa, FLJournal Editorial Board1) 2011-present Series Editor-in-Chief of the journal Clinical Translational Medicine (official journal of the International Society of Clinical and Translational Medicine)2) 2012-present Member, Editorial Board, Scientifica3) 2012-present Member, Editorial Board, Data Sets in MedicineLicensure and Accreditation2008-present Board of Registration in Medicine, State of Florida

Co-directed an NIH-funded pre-doctoral training program offered through the Clinical Translational Science Institute (UF), which was developed to provide scholarships to those graduate students affiliated with member colleges of the CTSI who wished to undertake didactics and practicum experiences (clinical exposure to outpatient setting as well as Clinical Research Center for Phase I/II studies, writing IRB applications, etc.) that would prepare them as leaders in the biomedical workforce with skill sets that facilitate clinical translational research. All applicants were required to have both a Basic Science and a Clinical Translational Research mentor.

Honors and Awards2012 Inaugural award for Innovations in Research Training and Education by the American Association of Medical Colleges (AAMC) Narrative AccountOn my first day as the Director, I could not find a complete list of all of the active MD-PhD scholars because there was effectively no administrative office. Other programs nationwide were under the impression that there was no MD-PhD training program at the University of Florida. During the 5+ years that followed, I brought the MD-PhD Training Program back to a nationally competitive status using paradigms of clinical translational medicine, team/consortium science and the social mission. Since July 2007, when I began my tenure as the Director, our independent training program for MD-PhD scholars has undergone a radical restructuring and transformation. The MD-PhD Training Program has steadily and appropriately evolved from its beginnings in 1967 to its current status as a nationally competitive program based on my belief that we need to train leaders in the biomedical workforce who can address urgent and unmet health care needs against the back drop of increasingly complex social challenges that have emerged over the past five decades. This evolution reflects a foundational educational philosophy that recognizes the importance of training clinician-scientists with highly developed skill sets in both traditional “wet lab” disciplines as well as disciplines in the quantitative, qualitative and social sciences (“beyond the wet lab”) to meet the anticipated needs of the future biomedical workforce. The adoption of paradigms such as clinical translational science (CTS), interdisciplinary and multidisciplinary team science, and a social mission is fully aligned with real world requirements for completing the clinical translational mission by closing the gap between discovery and health, and in a manner that furthers the goal of eliminating the health disparities gap.

I followed my research mentor, Dr. Joseph V. Bonventre, from the Massachusetts General Hospital (Harvard Medical School) to the Brigham & Women's Hospital after he became Chief of the Renal Unit.Honors and Awards1) 2005 National Kidney Foundation Clinician-Scientist Award, USA2) 2005 American Society of Nephrology Gottschalk Award, USAHospital or Affiliated Institution Appointments1) 2005-2007 Associate Physician, Brigham and Women’s Hospital (Harvard Medical School), Boston, MA2) 2005-2007 Physician, Faulkner Hospital (Harvard Medical School), Jamaica Plains, MA3) 2006-2007 Physician, Mount Auburn Hospital (Harvard Medical School), Cambridge, MAEditorial Boards1) 2004-2005 Executive Editor, Advances in Molecular Mechanisms of Diseases (Series), Special issue “Diseases of the Kidney: Molecular Mechanisms and Current Therapy” (2005) Current Molecular Medicine 5:1566-52402) 2005-2008 Member, Editorial Board, Journal of the American Society of Nephrology (USA)CommercializationOnly hybridoma that produces a high affinity IgG monoclonal antibody to the human cell cycle regulator and proto-oncoprotein TRIP-Br1 (clone TB1-27#2) in Spring 2007 (Alexis, Biochemicals; Switzerland)

Honors and Awards1) 1999 Best Basic Science Poster Award, 3rd NUH Faculty of Medicine Annual Scientific Meeting2) 2000 The Pharos Editor’s Prize for the essay “On Being a Scientist”3) 2001 Royal Society of Medicine Library Prize (2001) for textbook “Evidence-Based On Call: Acute Medicine.” Editors S. Straus, S.I.-H. Hsu, C.M. Ball, R.S. Phillips, Harcourt-Brace, UK 4) 2002 Singapore Biomedical Research Council Young Investigator Award (Inaugural Award)Major Administrative Positions1) 2001-2004 Associate Chairman (Research), Medical Board, National University Hospital, Singapore2) 2001-2005 Deputy Director, Office of Biomedical Research, National University Hospital, SingaporeHospital or Affiliated Institution Appointments1) 2000-2005 Senior Registrar, Renal Division, Department of Medicine, National University Hospital, SingaporePatentsUS patent entitled "Modulation of TRIP-Br function and a method of treating proliferative disorders" (Inventor: Stephen I-Hong Hsu) was awarded to the National University of Singapore on May 29, 2007

Established joint training program in Singapore for pre-doctoral (PhD) students between the IMCB and the Yong Loo Lin School of Medicine (National University of Singapore and National University Hospital).

Genome-wide association study of familial IgA nephropathy among Han Chinese from Singapore and Hong Kong

Licensure and Certification1997-present Diplomate in Internal Medicine, American Board of Internal Medicine1998-present Board of Registration in Medicine, Commonwealth of Massachusetts

I remember it as if it were just yesterday, entering the White Lobby of the entrance of the MGH on the first day of my internship on July 1, 1984. The entrance of "Man's Greatest Hospital" (heavy sarcasm) was as unassuming and unpretentious as one could imagine. It was conspicuously unimpressive. The austere entry was flanked by Corinthian columns, preserved to this day, the worn white marble floor of the lobby entrance not giving the slightest hint of the 200 year legacy of this institution that was originally founded in 1811 as an asylum for the insane. During the history of the largest teaching hospital affiliated with Harvard Medical School, great men and women of American medicine walked along the many marble floors of the MGH during their own training as physicians in the finest humanistic tradition, many of whom would go on to train countless other physicians and conduct seminal research as enduring contributions that are recorded in the annals of Western medical history. The White Lobby was not named after the white marble floor and walls and columns, but rather in commemoration of two great surgeons as I recall, brothers actually. Later, a cardiologist named Paul Dudley White would continue the family tradition, recognized by name for the description of a cardiac arrhythmia known as the Wolf-Parkinson-White Syndrome. One of my co-interns is named Adams Dudley. It seemed fitting to me, as I walked across the threshold on that first day, feeling the impossible weight of responsibility mixed with pride as a part of that legacy, that the MGH was never about its physical appearance or other trappings. Over the centuries, the structural expansion of the hospital would occur haphazardly, built layer upon layer without apparent rhyme or reason--a metaphor for the human person, as I came to understand it. The MGH had always been and would always be about the people who walked its halls--attending physicians, residents, patients, family members, and friends.